FBTCX Rating, Research - Fidelity Advisor Biotechnology C

Fidelity Advisor Biotechnology C (fbtcx)

Last Updated by Anonymous | Update This Page Now

►Summary | Add New Mutual Fund | Feedback

Short Term Rating Stock Ratings Help
placeholder_summary.png

Asset Allocation (% of Port)

US Stocks
Non-US Stocks
Bonds
Cash
Other
%
%
%
%
%

Geographic Allocation (% of Port)

North America
Europe
Asia
South America
Africa
Australia + Pacific Islands
Long Term Rating Stock Ratings Help

HOLD

SWOT Statistics

Strengths + Opportunities = 18

Threats + Weaknesses = 13

When strengths & opportunities substantially exceed threats & weaknesses an investment in the fbtcx mutual fund has great long term potential.

Fund Management Team

Fund Description Update

Fidelity Advisor Biotechnology C (FBTCX) Description: FBTCX is a mutual fund, which is an investment that owns a basket of assets. The FBTCX mutual fund was provided by Fidelity and this investment vehicle derives the majority of its value from equity holdings (stocks). Fidelitys mutual fund has a medium management tenure and is in the small fund size classification. FBTCXs minimum initial investment amount is $2500 while the IRA minimum is $500. FBTCXs expense ratio is roughly 2%. The latest FBTCXs front end load was 0% and the back end load was 1%. The Fidelity Advisor Biotechnology C (FBTCX) mutual fund falls under the health category. FBTCX focuses its investments in USA and FBTCX is focused on the health industry or fund sector. The Fidelity Advisor Biotechnology C (FBTCX) mutual fund is not a leveraged fund and it does not have inverse fund properties. An investor can find FBTCXs top holdings, fundamental analysis, ratings, and fund risk (volatility) on the left side of the screen. The right side of FBTCXs research report features technical analysis and long term investment potential.

Portfolio Strategy Update

This investment vehicle seeks capital appreciation. The fund normally invests primarily in common stocks (see stock research) and invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. It also invests in domestic and foreign issuers. The funds non-diversified.


Management Analysis Update


Performance Analysis Update